CD8A and breast carcinoma: This is the first study to demonstrate that high CD8+ TIL levels and CD8/FOXP3 ratio in residual tumors could accurately predict the better clinical outcome in TNBC patients with non-pCR following NAC and that the changes of these parameters in breast cancer tissues following NAC were also significantly associated with eventual clinical outcome in TNBCs.